Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of ICP-332 in moderate-to-severe atopic dermatitis
CTR20223209Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soficitinib in atopic dermatitis (AD), sponsored by InnoCare Pharma. Started Jan 2023; status: completed.
02
Drugs
soficitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20223209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223209.